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1. Introduction
Age-related maculopathy (ARM) and age-related macular degeneration (AMD) are stages in
a process of degeneration of the central macular region of the retina defined as occurring over
the age of 50. This chapter examines the evidence for environmental and genetic risk factors
for developing AMD.
2. Epidemiology
2.1. Burden and impact of disease
2.1.1. Incidence
Incidence rates for all ARM lesions increases significantly with age. In the Blue Mountains Eye
Study (BMES) Mitchell et al found overall 5-year incidence of late ARM lesions (combined
geographic atrophy and neovascular ARM), was 1.1%. Age specific rates were 0.0%, 0.6%,
2.4%, and 5.4% for participants aged 60 years and younger, 60 to 69 years, 70 to 79 years, and
80 years and older at baseline, respectively [1]. After excluding participants with either early
or late ARM in either eye at baseline, the overall 5-year incidence of early ARM was 8.7%,
(3.2%, 7.4%, 18.3%, and 14.8% for the corresponding age. The findings parallel those in the
Beaver Dam Eye Study (BDES) where it was noted those 75 years of age or older have
significantly higher 5-year incidence of exudative macular degeneration (1.8% vs. 0%), and
pure geographic atrophy (1.7% vs. 0%) than people 43 to 54 years of age [2].
Individual ARM fundus signs that predict best the development of AMD are large drusen (>
or =125 microm) [3], 10% or more of the grid area covered by drusen [3], soft indistinct drusen
[2] and focal hyperpigmentation [2;4]. There is a high risk of second eye involvement with
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annual incidence of CNV occurring in the second eye of patients with CNV in the first eye
reported as between 6-15% [5;6].
2.1.2. Prevalence
Age-related macular degeneration is the third largest world cause of visual impairment, and
in Western countries it is often the leading cause of blindness. In the UK and USA for example
it is the leading cause of blind registration [7;8 9;10] accounting for nearly 50% of blind and
partial sight registrations in all age groups and nearly 55% in the over 65 age group. There is
evidence to suggest the incidence of AMD is increasing. Evans and Wormald examined data
from the Office of Population censuses and Surveys in the UK and compared available data
for the years 1950, 1960, 1970 1980 and 1990 [11] and were able to demonstrate an increase in
percentage registrations due to AMD by 30%. Population studies give prevalence figures of
2-10% for ARM in the age range 50-75. Thereafter, the frequency rapidly increases to figures
of around 15% and nearing 50% in those over the age of 85. These prevalence figures vary
according to the diagnostic criteria used hence the studies performed to date, with the
exception of those using the International or Wisconsin grading systems, are difficult to
compare. Whether or not the incidence is increasing there is no doubt that with the ageing
population, the prevalence is increasing and the impact on the individual to be able to live
independently will also have an indisputable impact on society.
2.2. Impact of AMD on the individual
2.2.1. Mortality
There is some evidence to suggest that poor vision is associated with increased mortality and
co-morbidity in elderly people [12;13]; although interestingly those with much more severe
visual impairment may actually live longer, perhaps due to leading more ‘sheltered lives’ [14].
However recent data suggest that AMD in itself is not associated with increased mortality but
acts as a marker for other diseases which do [15].
2.2.2. Mental health, quality of life and well-being
Visual impairment has been shown to be more age-related than any other disability [7] and visually
impaired elders may be at more risk of affective disorders, particularly depression [16]. Wil‐
liams et al assessed the impact of AMD on quality of life and well-being [17]. The authors found
significantly poorer ratings for quality of life and emotional distress in patients with AMD
compared with age-matched adults and the rates were comparable with those reported for chronic
illnesses (e.g. arthritis, bone marrow transplantees, chronic obstructive airways disease) [18].
Unpublished data (Jan Mitchell BSc, Royal Holloway, University of London) indicates that the
Macular Disease Society Quality of Life questionnaire, incorporating the 12-item Well-being
questionnaire [19], in addition to questions specifically designed to measure the impact of macular
disease, showed a greater negative impact on most aspects of quality of life in macular degenera‐
tion compared with diabetes. In addition, attitudes of physicians was shown to add to the stress
such a diagnosis may have on an individual by giving an impression of lack of concern or interest
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in their patients and by inadequate dissemination of information about the condition or serv‐
ices available to aid their rehabilitation [18]. In a study by Lee et al, blurred vision caused greater
decrement in functioning and well-being than many other medical conditions including heart
disease, diabetes, hypertension, indigestion and headaches. Only shortness of breath had a greater
impact on these parameters than blurred vision [20]. The quality of life of community-dwelling
elderly people has been shown to be significantly linked to sensory impairment. Mood level and
social relationships are particularly affected by visual impairment [21]. A survey, using the VCM1
questionnaire [22] (a questionnaire designed to measure vision-related quality of life) lead to an
estimate of more than 550,000 individuals in England with substantial vision-related quality of
life impairment [23].
2.2.3. Falls and functional ability
Falls among the elderly are a major cause and result of morbidity and studies indicate that 30%
of persons over the age of 65 may suffer a fall each year, increasing to 40% in those over 80 [24].
Tinetti et al demonstrated that although visual impairment was not the single most common
cause of falls in the elderly it had a significant additive effect in this multifactorial condition
[25]. Other studies have been able to show a significant positive association between reduced
contrast sensitivity, reduced visual acuity and self-reported visual impairment [26;27] and
falls. Older people tend to need to rely more on vision to maintain vertical posture [28]. Hip-
fracture is clearly a serious consequence of falls in the elderly and has provided an objective
outcome measure in assessing the relationship between poor vision and falls in the elderly.
Cummings et al performed a detailed prospective study of 9516 white women over 65 years
of age and found that poor contrast sensitivity and reduced depth perception were independ‐
ent risk factors for hip fracture [29]. The Blue Mountains Eye Study has subsequently confirmed
that measured visual impairment is associated with both falls and hip-fracture [30].
2.2.4. Driving and independence
Independence is an important measure of quality of life for older people. Being able to continue
driving is often seen as the most valuable means of maintaining this independence. Macular
degeneration and macular haemorrhage were found in one study to be among the six most
frequent medical conditions for driving cessation in community-based ambulatory individuals
over the age of 70 [31]. Evidence exists to show that older drivers with visual impairment and/
or a constriction in the size of the useful field of view to be at greater risk for vehicle crashes
than those without these problems [32]. Studies have also been able to show in more general
terms loss of independence for example, in a survey by Branch et al of self-reported vision loss
in those over the age of 65 Activities of Daily Living needs such as housekeeping, grocery
shopping, and food preparation were largely unmet [16] and Williams et al found that people
with macular degeneration were more likely to need help with daily activities [17].
2.3. Impact of AMD on society
It is difficult to quantify the financial burden of AMD disease on society and there have
been few studies specifically addressing this complex subject. In the UK for example, the
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National  Health  Service  (NHS)  spends  more  than  £20  billion  per  year  on  long-term,
residential and home care and it can be envisaged that redirecting a fraction of this sum
towards helping people maintain independence such as by the provision of inexpensive
low vision aids may save billions of pounds per year [33]. Scuffham et al [34] examined
the cost of injurious falls associated with visual impairment in the UK and showed that
the  National  Health  Service  currently  spends  £1.7  billion  per  year  treating  hip  fracture
resulting from falls and given that older people with sight problems are more likely to fall
than  non-visually  impaired  older  people  this  sum  might  be  significantly  reduced  by
attending to visual impairment. Studies have also looked at individual ocular diseases in
order  to  quantify  the  cost-effectiveness  of  treatment  verses  no  treatment  which  is  an
important  consideration  with  an  ever  increasing  financial  burden  of  healthcare  [35].
Photodynamic  therapy  (PDT)  and  the  use  of  Anti-Vascular  endothelial  growth  factor
(VEGF) treatments have highlighted this controversy and rationing in health care has, as
yet,  prevented this treatment from being made available to all.  Sharma et al determined
the cost-effectiveness of PDT for the treatment of subfoveal choroidal neovascularisation
(CNV) in patients with disciform degeneration in one eye and who’s second and better-
seeing eye develops visual  loss secondary to predominantly classic  subfoveal  CNV. The
authors concluded that PDT can be considered to be a treatment that is of only minimal
cost-effectiveness for AMD patients who have subfoveal CNV in their second and better-
seeing eyes and who have good presenting visual acuity at baseline and is a cost-ineffec‐
tive  treatment  for  AMD patients  who have poor  visual  acuities  in  their  affected better-
seeing eyes [36]. However the same authors also examined the expected gain in quality of
life-adjusted life-years (QALYs) associated with photodynamic therapy for the treatment
of subfoveal CNV. Photodynamic therapy was associated with a relative increase in QALYs
of  11.3%  compared  with  placebo  [36].  This  example  alone  highlights  the  problems  of
attempting to cost quality of life.
Epidemiological data for many of the issues outlined here is often scarce and may be non-
comparable between studies, however epidemiological studies remain an important tool for
assessing the distribution and determinants of disease in a population and can be used to
evaluate interventions.
3. Risk factors for AMD
The search for modifiable risk factors for AMD has gained impetus over the past two decades
and this has largely stemmed from the development of clearer definitions of disease. The
advent of appropriate grading scales [37;38], knowledge of natural history and progression
and the identification of sub-types of AMD, enables comparison and corroboration of data
between studies, adding weight to putative risk associations. However, some of the data can
be conflicting due to the large numbers of possible risk factors assessed. Despite the limitations
of these studies, there has been consensus that age, smoking and genetic make-up are risk
factors for developing AMD.
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3.1. Demographics
3.1.1. Age
Age is the strongest risk factor for AMD and ARM. An age of 50 yrs was taken to be the
minimum criteria for the findings of drusen and other changes to be described as ARM in the
International Classification System of age related maculopathy [37] and this has generally been
accepted as the cut-off for defining maculopathy as being age-related. In a meta-analysis all
studies found a strong association with increasing age [39]. Population studies universally
show increasing prevalence with age [9;40-43]. A meta-analysis of three large population
studies by Smith et al gives age-specific prevalence of sub-groups of ARM and AMD [44]. The
authors reviewed the findings from the Beaver Dam, Rotterdam and Blue Mountains eye
studies. All these studies used the Wisconsin grading system for ARM and AMD enabling
direct comparisons between prevalence rates. The AMD lesions, namely geographic atrophy
(GA) or choroidal neovascularisation (CNV) were found to have an overall prevalence of 1.63%
in the populations when combined (note: the age range was from 43-99 years overall but in
the analysis by Smith et al they only reviewed the data on the age range common to all three
studies which was 55-86). These specific AMD lesions were not found in anyone below the age
of 55 years in any of the populations. The incidence of AMD rises with age being 0.21% in those
55-64, 0.85% in those 60-74 then a dramatic rise to 4.59% in those 75-84 and 13.05% of those
aged 85+ [45]. The average age at which wet AMD develops is 75 years [46]. Incidences of
drusen, RPE changes, geographic atrophy, and exudative disease all increase, as exemplified
by the 8- to 17-fold increased risk of developing AMD demonstrated between ages 50 and 90.
3.1.2. Gender
The evidence is conflicting for gender as a risk factor. The Beaver Dam eye study indicates
both a higher incidence of early ARM in women over the age of 75(ratio 2.2:1) [2] and a higher
incidence of exudative AMD in this same age group (ratio 2.6:1) [9]. This difference was not
explained by selective mortality. Other studies have not been able to demonstrate this clear
sex prevalence. In the Rotterdam study presence of hypo- or hyperpigmentation was higher
in men but there was no difference in the sex ratio for atrophic (GA) or neovascular AMD [41].
Mitchell et al in the Blue Mountains Eye Study found consistently higher rates for AMD in
women in each 10-year age-group but this difference was found not to be significant when
adjusting for age in a logistic regression. They also used the same statistic on the figures from
the Beaver Dam eye study using an age-adjusted relative risk of 1.27 and found the sex
difference to be non-significant. Smith et al [44] found there to be no difference in the age-
specific prevalence of AMD between men and women in the Beaver Dam, Rotterdam and Blue
Mountains studies. Evans summarises this well and concludes that, although more studies
have demonstrated a slight increased risk in women in the older age-groups, it could not be
confirmed that all age-effects and health-seeking behaviours were taken into account [47]. The
meta-analysis by Chakratharty et al suggests that there is no significant association between
female gender and late AMD. In the case control studies included in the analysis, the overall
AMD: Epidemiology and Risk Factors
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OR for female gender was 1.00 (95% CI 0.83 - 1.21). In the cross-sectional studies, it was 1.06
(95% CI 0.78 - 1.44) and in the prospective studies, it was 1.01 (95% CI 0.89 - 1.16) [39].
3.1.3. Ethnicity
Several studies have looked at incidence and prevalence by ethnicity and there are established
differences. Comparison of the three large population studies from Holland, the US and
Australia demonstrated a lower prevalence of neovascular AMD in the Dutch population [44].
All late forms of AMD appear to be more common in the White population as compared to
Black and Hispanic populations [48;49]. However the highest frequency for exudative AMD
appeared to be in Chinese (age- and gender-adjusted odds ratio, 4.30; 95% confidence interval,
1.30-14.27) compared with whites [50]. Choroidal melanin has been hypothesized to have a
protective effect on the RPE, photoreceptors, and Bruch′s membrane, perhaps through an
antioxidant effect or an ability to absorb light rays that damage the posterior layers of the retina
[51]. However, in most of these studies that included both whites and blacks, there were too
few blacks with neovascular AMD to examine the reason for these racial differences. Although
the incidence of neovascular AMD in blacks is lower, it is not negligible. Data from one recent
study, the Salisbury Eye Evaluation, showed that the prevalence of choroidal neovasculariza‐
tion was 1.1% in blacks, compared with 1.7% in whites [52].
When examining specific features of age-related macular change, the Baltimore Eye Survey
found large drusen (>125 microm), pigment abnormalities and AMD were more common
among older whites compared with blacks. The prevalence of AMD was 2.1 % among whites
over 70 years of age. No cases of AMD were detected among 243 black subjects in this age
group [53]. In addition the spectrum of neovascular maculopathy in black Americans was
found to differ from that typically seen in whites, both clinically and demographically. In a
retrospective review of over 100 angiograms for AMD, CNV in blacks was more commonly
juxtapapillary and more had CNV in the absence of drusen or other known predisposing
conditions. Disciform-stage CNV in blacks was associated with a greater degree of pigment
proliferation than that typically noted in whites. Demographically, there was a significant
female predominance of CNV in blacks (87%) compared with population studies [54]. In
Vancouver a total of 88 ethnic Chinese patients were identified among 10,000 angiograms.
Pigment epithelial detachments were more than twice as common in the overall group of ethnic
Chinese patients as in their counterparts of European ancestry (OR 2.6, 95% CI 0.7 to 10.1). The
relative prevalence of the two main late AMD subtypes (GA and CNV) varies according to the
population studied. In the Beaver Dam [9], Rotterdam [41] and Blue Mountains [42] eye studies
the overall ratio of GA to CNV was 1:2. Whereas in the Reykjavik eye study [55] the ratio is
reversed with an overall relative prevalence of GA to CNV of 4.5:1 (3: 1 in those 70+) but it was
noted that a common ancestor was found in those with GA only 6 generations back compared
with the norm of 12 generations in the Icelandic population. In Japan there is evidence that
AMD is increasing quite dramatically which would refute the idea of a racial component to
the disease and would imply that lifestyle factors may be more important. The number of
exudative AMD patients in all ophthalmology departments throughout Japan was estimated
to be 14,400 in 1993. This number was estimated to have almost doubled over the six year
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period since the initial survey in 1987 [56]. In Greenland an unusual form of AMD is described
as retino-choroidal atrophy (RCA). The clinical picture of RCA is peripapillary and central
retino-choroidal atrophy and sclerosis. In 1997 Ostenfeld-Akerblom et al examined 22 patients
with AMD and of these 12 patients had RCA, which was the most common type of AMD in
this Greenlandic investigation. All were severely visually handicapped with a visual acuity
less than or equal to Snellen 6/60 [57]. Similarly, in African-Americans and Asians the pattern
of disease does appear to be different with polypoidal chorio-vasculopathy (PCV) being more
common [58].
3.1.4. Geography
It is difficult to separate the effects of geography from race and there is little evidence to suggest
that geography per-say has an influence. However it has been shown that the prevalence in
immigrants tends towards that of the native population and the assumption is that diet and
lifestyle influences disease presentation [59;60].
3.1.5. Socioeconomics
It has been shown that visual impairment reflects socioeconomic status [61] and there is limited
research specifically looking at the socio-demographics of people with age-related macular
degeneration. However after controlling for smoking, age, sex and less vitamin supplemen‐
tation Klein et al [62] found incidence of early ARM was highest in those in the service
industries and blue collar workers and in those with less formal education. The association of
early and late ARM with less education was also demonstrated in the AREDS study [63] and
the EDCCS demonstrated an association of less education with CNV [64]. The Beijing eye study
shows conflicting evidence with an early report noting early ARM was statistically associated
with living in a rural region (p<0.001; 95% CI: 0.17 to 0.49) and lower level of education (p =
0.01; 95% CI: 1.07 to 1.65) [65] but a later report showing no statistical association [66]. In
another Chinese study, high educational background was a protective factor for AMD (OR:
0.761, 95% CI: 0.51-0.98) [67]. However other studies have not been able to show an association
[48;68-71]. The difficulty of establishing a link with socioeconomic status is that in itself it
comprises many facets and confounders are thus difficult to quantify but the majority of cross-
sectional studies appear to support an association with lower levels of education.
3.2. Personal characteristics
3.2.1. Hair colour / skin sun-sensitivity
Although sun-exposure might in itself be a risk for AMD, it is recognised that sun-sensitivity
and sun-avoidance may be confounding factors [72]. In the case-control study by Darzins et
al [73] they were able to demonstrate significantly poorer tanning ability (skin types I or II) in
cases with AMD in chi-squared analysis. However, age and smoking as well as sun-exposure
are all possible confounders and were not included in the analysis. Data from the Blue
mountains study [72] indicated greater skin sun-sensitivity in those with AMD but also
reduced skin sun-sensitivity; possibly explained by increased biological risk in those with
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sensitive skin but overridden by sun avoidance in those with average tanning skin and but
increased sun exposure in the darker skin category. Khan et al found no association between
skin sun-sensitivity and late AMD [74]. Hair colour may be associated with ocular pigmenta‐
tion and has also been postulated as a possible identifiable risk factor for AMD, however no
association was found in either the Blue Mountains Eye Study or the case-control study by
Khan et al [72;74].
3.2.2. Iris colour
Four case-control studies have demonstrated an association between light iris colour and
macular degeneration [75-78]. Three of these studies looked at cases with a broad definition
of macular degeneration, which included cases of ARM as well as AMD [75-78], and all
appeared to shown an association of AMD with lighter iris pigment. However, the control
groups are not clearly defined in two of the studies [76;77], the studies did not always define
a specific grading protocol for iris colour and did not look at potential confounding factors
such as smoking and age in a logistic regression approach. Khan et al, in a study of well-defined
GA and CNV with adjustment for potential confounders, showed that whilst there was a trend
for lighter iris colour to be associated more frequently with geographic atrophy type AMD,
this did not reach clinical significance. In a case series, Sandberg et al suggest that light iris
colour may be associated with more severe neovascular AMD with more extensive retinal
degeneration [79] than might occur in patients with darker irides. Holz [80] demonstrated that
iris colour per-say may not be linked to ARM but that a change in iris colour with loss of stromal
pigmentation may be associated with increased risk of ARM. The grouping of different
phenotypes of AMD in some studies may have diluted any association of iris colour and AMD
and hence it is difficult to be certain if there is any true association. Iris colour has also been
explored in population studies [64] however, the numbers of late AMD may have been too
small to detect any association. In the Blue Mountains eye study [72] an association was
detected for blue iris colour alone when compared with all other iris colours, in both late AMD
and early ARM and this was using a multiple logistic regression approach correcting for
confounders of smoking, age, gender and family history of AMD. Lighter-coloured irides were
associated with GA (OR, 5.0; 95% CI, 1.0, 25.3) in the Latinos Los-Angeles eye study [81]. On
balance, whilst there may be a small association between lighter iris colour and AMD, the effect
appears to be small and other risk factors are likely to outweigh any effect of iris pigmentation.
3.2.3. Refractive error and axial length
Several authors have demonstrated a relationship between hyperopia and AMD, more
specifically CNV. Sandberg and co-workers found patients with unilateral neovascular AMD
had an average spherical equivalent that was 1.0 diopter (D) more hyperopic than that of
patients with the bilateral dry form. Patients with a refractive error of +0.75 D or greater were
more likely to have the neovascular form compared with patients with other refractive errors
[82]. A number of case-control and population cross-sectional studies also confirm an associ‐
ation with shorter axial length and AMD [83 63;84 85]. In the Beijing eye study, hyperopic
refractive error, besides age was the single most important risk factor for ARM in adult Chinese
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[65]. It is thought that hyperopia might cause secondary changes in the choroidal vasculature,
predisposing them to choroidal neovascularization [86].
3.3. Genetics
The first information assessing genetic risk was demonstrated in twin and familial aggregation
studies. Candidate gene studies then attempted to associate putative disease-causing poly‐
morphisms with disease, but this relied on scarce knowledge of gene function and disease
pathways. Thus initial studies examined known monogenic macular dystrophies as potential
candidate genes. Non-retinal disease-causing genes then began to be explored and with the
discovery of an association of APOE variants with AMD. This opened up new avenues for
exploring other ‘house-keeping’ genes as potential candidates in AMD.
Major breakthroughs then came with family-based linkage studies of affected siblings, which
identified a number of genetic loci. Thus genes known genes in these regions could be targeted
and case-control association studies initially also played a role in discovering the major genetic
variants for AMD. In 2010, several large-scale genome-wide association studies (GWAS)
identified genes that had not been previously identified.
3.3.1. Family history and twin studies
There  is  strong  support  now  for  a  genetic  basis  to  AMD  and  ARM  [87](major  review).  Evi‐
dence  arises  from  a  number  of  sources.  Initially  twin  studies  [88-92]  demonstrated
concordance  in  Monozygotic  twins,  greater  than  in  dizygotic  twins.  Population  [93-95].
There have been relatively few studies quantifying the influence of family history [75;93;94;
96-99], with estimates of the odds ratio for a positive family history conferring risk of AMD
ranging from 2 to 27 [75;93;94;96;97;100].
3.3.2. Linkage studies and genome-wide association studies
Genetic linkage studies [101-103] have identified genes in large families which associate with
disease. Two major disease susceptibility loci have been confirmed in a number of studies;
chromosomes 1q32, which includes the gene that encodes complement factor H [CFH] and
chromosome 10q26 [104;105](meta-analysis), (includes PLEKHA1, hypothetical gene
LOC387715, and HTRA1). In one study genetic variation in VEGF showed evidence of linkage
(HLOD = 1.32) [106] and this has been confirmed in other studies [107]. Further novel variants
have been found in the TNXB-FKBPL-NOTCH4 region of chromosome 6p21 in a recent
genome-wide association study and this requires further exploration.
3.3.3. Candidate gene studies
A number of autosomal genes associated with hereditary retinal dystrophies have been
isolated with the majority assessed as potential candidate genes for AMD (RetNet Retinal
Information Network at http://www.sph.uth.tmc.edu/retnet/). Attention has focused on those
with phenotypic similarity to AMD. Stargardt disease and Best macular dystrophy commonly
result in high levels of retinal pigment epithelial autofluorescence and macular atrophy.
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Drusen are a prominent feature of Doyne honeycomb retinal dystrophy (autosomal dominant
radial drusen; Malattia Leventinese) followed later by the development of CNV, which is also
a common feature of Sorsby fundus dystrophy.
Genes associated with hereditary retinal dystrophies are not the only candidate genes for
AMD. Data on environmental risk factors suggest other pathogenic processes to be explored.
Positive associations have been found for proteins involved in the biological infrastructure
such as the extracellular matrix [108], and the RPE [109]. Genetic polymorphisms in genes
controlling angiogenesis have also been investigated [110;111]. Genes controlling lipid and
cholesterol transport [112-116] have also been implicated. Apolipoprotein E (ApoE), a major
lipid transporter, has two alleles of interest: ε2 and ε4. ApoE ε4 was the first gene identified
that appeared to confer resistance to the disease (OR 0.43; 95% CI 0.21-0.88) [113;114]. Con‐
versely, ApoE ε2 confers susceptibility to AMD.
The inflammation and immune response has been examined in greater detail since linkage
studies revealed common variants found in complement factor H (1q) [117-119] associated
with disease. CFH is a major regulator of complement cascade which is part of the innate
immune system. Risk of developing AMD is associated with an allele of CFH in which a
histidine residue is encoded in place of a tyrosine residue at amino acid position 402. The
increased risk ranges between 2- to 4-fold for heterozygote carriers and 3- to 7-fold for
homozygotes. In addition, multiple other polymorphisms, many of which are in non-coding
regions of CFH or in nearby genes encoding other complement factors, demonstrate equal or
stronger association with disease susceptibility than does the CFH Y402H variant [120;121 122].
No single polymorphism accounts for the entire contribution of CFH to disease susceptibility
and there appears to be a number of polymorphisms, some conferring risk, others reducing
risk [123;124]. At 10q26, a number of genes have been implicated. A single nucleotide poly‐
morphism (SNP) in the promoter of the HTRA1 gene was associated with a population
attributable risk of 49.3% and a 10-times greater risk of developing CNV [125]. Another
susceptibility locus PLEKHA1/ LOC387715 also mapped to chromosome 10q26 [126;127]. In
the study by Jakobsdottir, the association of either a single or a double copy of the high-risk
allele within the PLEKHA1/LOC387715 locus accounts for an odds ratio of 5.0 (95% confidence
interval 3.2-7.9) for ARM and a population attributable risk as high as 57%.
3.4. Systemic disease
Epidemiological studies have primarily investigated hypertension and hyperlipidaemia, and
the clinical manifestations of CVD such as myocardial infarctions and angina [128], although
some other chronic diseases have also been investigated. Although the overall number of
participants in these studies is large, there may be low prevalence of end-stage cases and in
the longitudinal population studies, few incident cases. Therefore the power to test for
statistically significant associations is weak, unless the relative risk is very high. Failure to find
associations may also be due to the insensitivity of some of the risk factor measurements or
due to selective survival. Conversely, some of the relations reported may be due to chance,
bias, and unadjusted confounding.
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3.4.1. Cardiovascular disease
Risk factors for cardiovascular disease (such as age, smoking, hypertension, hypercholester‐
olemia, post-menopausal estrogen use, diabetes, and dietary intake of fats, alcohol and
antioxidants) have been associated with AMD in some studies. This raises the possibility that
the causal pathways for cardiovascular disease and AMD may share similar risk factors [129].
However, few studies have looked at cardiovascular disease as a risk factor in its own right.
In one case-control study there was a statistically significant association between coronary
artery disease and AMD [83], but in the prospective case-control Age-Related Eye Disease
Study (AREDS) study of 776 subjects there was no increased incident AMD with mean 6.3
years follow-up with a history of angina as a measure of cardiovascular disease [130]. A large
population study, the National Health and Nutrition Examination Survey (NHANES) III
showed dry AMD was with myocardial infarctions in non-Hispanic white subjects [48]. Other
population-based studies have not found an association [44;131-139]. A retrospective study of
Medicare records investigated the relationship between AMD and myocardial infarctions,
diabetes mellitus, and hypertension [140]. They used a five percent random sample of 2000 to
2003 Medicare enrolees which included 134,246 people with dry AMD and 32,788 people with
wet AMD. All three diseases were associated with AMD, particularly wet AMD, and baseline
AMD was significantly associated with the development of incident myocardial infarction
from which they suggest the possibility of shared common antecedents between myocardial
infarction and AMD.
3.4.2. Blood pressure
A number of population-based cross-sectional and case-control studies have found an
association between systemic hypertension and AMD [63;69;83;140-143]. The relationship
appears to be complex, with the association was significant only for wet AMD in two of the
studies63;143 and the association became statistically non-significant when dry and wet AMD
were analysed separately in another [83]. The Beaver Dam Eye Study (BDES) found that
systemic hypertension was associated with incident AMD and wet AMD at 10-year follow-up
[135]. There were differences noted in this study between the association of systolic and
diastolic blood pressure, with systolic BP showing a positive association with both wet AMD
and RPE depigmentation while diastolic BP was inversely associated with incident early ARM.
An inverse relationship between systolic BP and wet AMD was reported by the Women’s
Health Initiative Sight Exam Ancillary Study [139]. Other case-control and population studies
have not been able to detect a statistically significant relationship between AMD and hyper‐
tension which may reflect uncontrolled factors such as treatment for or duration of hyperten‐
sion [44;75;130-134;136-138;144-149].
3.4.3. Atherosclerosis
The Atherosclerosis Risk in Communities Study (ARIC) and the Rotterdam Study have
investigated relationship of atherosclerosis as a risk factor for AMD [128;133;150] using
ultrasound measurements of the common carotid intima-media thickness and to assess the
presence of atherosclerotic plaques. carotid artery plaque (odds ratio, 1.77; 95% confidence
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interval, 1.18-2.65) and focal retinal arteriolar narrowing (odds ratio, 1.79; 95% confidence
interval, 1.07-2.98) were associated with retinal pigment epithelial depigmentation only in the
ARIC study but no association was detected for AMD. In the Rotterdam Study atherosclerosis
was noted to be associated with a 2.5 to 4.7 times increased risk of AMD [150], suggesting there
may be similar pathways in the disease process or that it might directly influence pathogenesis
due to altered ocular blood flow.
3.4.4. Haematological- lipids/ Inflammatory markers
Cholesterol has been found in drusen deposits [151], and dyslipidemia, being an established
risk factor for atherosclerosis might also be a risk factor for AMD. Two 10-year follow-up
reports of population-based cohort studies and a case-control study have found a significant
association for HDL and AMD, however both protective and adverse effects have been
reported. The prospective studies also found an increasing trend of elevated total/HDL
cholesterol ratio with AMD, and pure geographic atrophy [135;152]. In contrast, population-
based cohort studies have not demonstrated a significant association between inflammatory
markers and AMD [152;153].Other biochemical risk factors for CVD that have been investi‐
gated for their association to AMD are serum lipids, fibrinogen and C-reactive protein (CRP).
Fibrinogen and CRP are inflammatory biomarkers shown to predict CAD [154]. Most studies
have not found any association between serum total cholesterol, HDL and LDL cholesterol, or
triglyceride levels and AMD [44;48;69;132;134;141;155 156;157]. Fibrinogen was positively
associated in the baseline analysis of the BMES population, however this relationship became
non-significant at the 10-year follow-up [132;152]. Seddon et al reported that CRP was posi‐
tively associated with progression of AMD in a clinic-based cohort. Similarly, cross-sectional
and case-control studies have shown positive relationships [48;132;153;158]. These findings
support an inflammatory aetiology for AMD pathogenesis with a minor, if at all, contribution
from serum lipids.
3.4.5. Stroke
Most studies have been unable to find an association between stroke and AMD [131 132 48 44;
133;134 135;136;139]. In the ARIC study early ARM predicted incident stroke in middle-aged
persons, however there were too few cases of late AMD to establish any association [159]. This
finding is supported with incident early ARM predicted by stroke in the Blue mountains eye
study [152]. Thus far, an association between late AMD and stroke has not been established.
3.4.6. Body mass index
There have been some positive associations noted between high BMI and early AMD.
[135;139;152;160-162]. In the AREDS study, greater body mass was found to be associated with
higher risk of incident GA after mean follow-up of 6.3 years [130]. Also Seddon et al specifically
evaluated progression from early or intermediate AMD to advanced AMD and demonstrated
an increased risk with higher BMI. [160]. However, pooled analyses of 3 large population
cohort studies have found no association between BMI and AMD [44;136]. In fact, in some of
these studies there has been shown an association of lean body mass with increased risk of GA
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[132;135;161] this association was not found in the AREDS. It therefore appears the association
is not yet universally established.
3.4.7. Diabetes
Diabetes may theoretically be a risk factor for AMD by influencing choroidal blood flow [163]
and increased plasma fibrinogen which may independently be associated with AMD [132].
Associations have been made between diabetes and wet AMD in some studies
[130;139;140;163]. But there is little evidence of an association with dry AMD [130, 139, 140].
Interestingly, the BMES found no association with wet AMD, but a significant relationship
with dry AMD [164]. In a meta-analysis, estimates from four prospective cohort studies
demonstrated the presence of diabetes to be associated with an increased risk of late AMD (RR
1.66; 95% CI 1.05 - 2.63) [147;152;165;166] and similarly meta-analysis of data from two cross-
sectional studies [167] associations were non-significant (OR 1.09; 95% CI 0.61 - 1.92). One case
control study [148] showed non- significant association with diabetes (OR 0.55; 95% CI 0.06 -
4.87). Certainly the evidence points to only a weak association between diabetes and AMD.
3.4.8. Other chronic diseases
Some diseases which have been postulated to have common pathogenesis with AMD include
Alzheimer’s disease (AD), gout and emphysema. In the Beaver Dam Eye Study, a history of
emphysema at baseline was associated with the incidence of retinal pigment epithelial
depigmentation (RR = 2.84; 95% CI, 1.40-5.78), increased retinal pigment (RR = 2.20; 95% CI,
1.11-4.35), and exudative macular degeneration (RR = 5.12; 95% CI, 1.63-16.06). A history of
gout was associated with the incidence of pure geographic atrophy (RR = 3.48; 95% CI,
1.27-9.53) [168]. Whilst in the Rotterdam population based study, although advanced age-
related maculopathy at baseline showed an increased risk of incident Alzheimer's disease
(relative risk = 2.1), this risk decreased after additional adjustment for smoking and athero‐
sclerosis (relative risk = 1.5). In a further population study, cognitive scores were lower in those
with AMD even after correcting for education although Alzheimer disease was not associated
with AMD. Other investigators have looked at the relationship between the CFH Y402H
polymorphism (now considered a major risk gene for AMD) and Alzheimer disease but the
association in one study was null [169]. Whilst in a further study, although an increased
frequency of the CFH AMD-risk polymorphism was noted in those with AD, subgroup
analysis showed that the association between CFH C allele and AD was only evident for
individuals carrying the APOE epsilon4 allele indicating a possible association between these
genes and disease phenotypes. Conversely a Hungarian study, whilst supporting the findings
of others of an association between the AMD-protective and AD-risk with APOE epsilon4,
found that AMD is rare in those with AD which is logical if the ApoE is a major determinant
of risk in this population.
3.5. Lifestyle
Along with identifying disease and co-morbidity as potential modifiable risk factors for AMD
there has also been extensive investigation of environmental and social risk factors. Smoking
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is the single consistent factor identified by the majority of studies. Evaluation of dietary factors
and sun-exposure has been less consistent, which may partly be due to the complexity of
measuring these factors.
3.5.1. Smoking
Of the many environmental factors investigated in relation to AMD, smoking is the one most
consistently found to be associated with increased risk. Several case-control and population
based studies have reported odds ratios typically in the range 2–5
[44;170;171,63;64;134;144;170-174]. However this has not been completely consistent finding
with a few smaller studies showing no association [69;75;83;148;175;176]. McCarty et al11
argued that total length of time of smoking was the most significant factor for development of
AMD rather than pack years or current or former smoking status. However, Khan et al
demonstrated that, whilst a loose definition of smoker or non-smoker did not show a statisti‐
cally significant relationship with AMD, when careful calculation of pack-years of smoking
was measured, this showed a strong association with both CNV and GA. Risk was also
influenced by living with a smoker which highlights an important public health message in
demonstrating the likely increased risk with passive smoking [177]. Stopping smoking was
associated with reduced odds of AMD in this study and the risk in those who had not smoked
for over 20 years was comparable to non-smokers. Studies have also shown that ceasing
smoking reduces risk even in those older smokers (over age 80) [178]. In the recent Eureye
study, bilateral disease was associated with increased odds of heavier smoking in the preced‐
ing 25 years [179].
Experimental evidence also supports smoking as a risk factor for AMD. The foveal region of
the retina has a yellow pigmentation composed primarily of the carotenoids lutein and
zeaxanthin. A variety of evidence suggests that this macular pigment protects the macula from
actinic damage both passively (by screening potentially harmful short-wave light) and actively
as an antioxidant (by quenching reactive oxygen species). Studies have shown that cigarette
smoking depresses carotenoid concentration in the blood [180]. In a study by Hammond et al
[181] macular pigment density and smoking frequency were inversely related (r = -0.498 P <
0.001) in a dose-response relationship. Smoking also has an established role in upregulating
inflammatory mediators [182,183] and contains the pro-oxidant hydroquinone [184] causing
further oxidative damage.
3.5.2. Sun exposure
Logically increased sun-exposure could increase the exposure of the retina to oxidative
processes. In experimental studies photic injury is frequently used as a model of oxidative
stress. In epidemiological studies, the measurement of sun-exposure generally relies on recall
diaries so evidence from epidemiological and basic scientific investigations unfortunately
gives somewhat conflicting results.
Experimental evidence to suggest sunlight as a risk factor is given by in-vitro studies. In the
retina, lipofuscin is located within the pigment epithelium where it is exposed to high oxygen
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and visible light, a prime environment for the generation of reactive oxygen species. It has
been demonstrated that retinal lipofuscin is a photo-inducible generator of reactive oxygen
species and this may translate into cell damage via several mechanisms. The position of
lipofuscin within the lysosome implies that irradiated lipofuscin is liable to cause oxidative
damage to either the lysosomal membrane or the lysosomal enzymes. One study group found
that that illumination of lipofuscin with visible light is capable of extragranular lipid peroxi‐
dation, enzyme inactivation, and protein oxidation. The authors postulate that lipofuscin may
compromise retinal cell function by causing loss of lysosomal integrity and that this may be a
major contributory factor to the pathology associated with retinal light damage and diseases
such as age-related macular degeneration [185]. It has also been shown that lipofuscin-loaded
RPE cells are considerably more sensitive to visible blue light than unloaded control cells. The
loaded cells showed lysosomal membrane destabilization with ensuing leakage of lytic
enzymes and eventually cell death [186]. Macular pigment, consisting of lutein and zeaxanthin,
through its ability to filter light and by direct antioxidative properties, has been proposed as
the most effective protective factor in the central retina ("natural sun glasses") and could be
important to reduce light-induced oxidative retinal damage. The observation, that with age
and especially in eyes with AMD, lower concentrations of macular pigment could be found,
can be interpreted that low macular pigment concentrations may be associated with higher
risk for AMD. Through dietary intake and eventually with supplementation the concentration
of macular pigment can be increased, and analysis of the correlation between macular pigment
and AMD may be important to characterise a possible modifiable AMD risk factor [187].
One of the first studies to examine the relationship of AMD to sun exposure was a case-controls
study by Hyman et al [75] of 228 cases; no association with AMD demonstrated. A larger study
of the Chesapeake Bay Waterman [176] found that even with high levels of UV-B or UV-A
exposure, there was no evidence of increased risk of age-related macular degeneration [176].
However a further report from the same study calculated that compared with age-matched
controls, patients with advanced age-related macular degeneration (geographic atrophy or
disciform scarring) had significantly higher exposure to blue or visible light over the preceding
20 years (odds ratio, 1.36 [95% CI 1.00 to 1.85]). The data suggests that high levels of exposure
to blue or visible light may cause ocular damage, especially later in life, and may be related to
the development of age-related macular degeneration [188]. Cross-sectional data from the
BDES also suggests that the amount of leisure time spent outdoors in summer was significantly
associated with exudative macular degeneration (OR, 2.26; 95% CI, 1.06 to 4.81) and late
maculopathy (OR, 2.19; 95% CI, 1.12 to 4.25). Whereas, wearing eyeglasses was inversely
associated with increased retinal pigment and the use of hats and sunglasses was inversely
associated with soft indistinct drusen [189]. Data from the Blue Mountains Eye Study [72]
indicated increased risk of late AMD associated with both high (OR, 2.54) and low (OR, 2.18)
skin sun sensitivity; possibly explained by increased biological risk in those with sensitive skin
but increased sun-exposure in the darker skin category. It was postulated that there may be
significant confounding by skin sensitivity and sun avoidance.
No support was found for sunlight exposure as a risk factor for AMD in several other case-
control studies [64;73;74;144;167]. Subjects In the POLA Study who had used sunglasses
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regularly had a decreased risk of soft drusen (OR = 0.81; 95% CI, 0.66-1.00) but the study did
not support a deleterious effect of sunlight exposure in ARMD [167]. In a study of 3271 people
in 9 randomly selected urban clusters and 4 randomly selected rural clusters in Victoria,
Australia, lifetime sunlight exposure and UV-B exposure was not associated with AMD [144].
In the Newcastle (Australia) study, after stratifying by tanning ability, the median annual sun
exposure of control subjects exceeded that of cases and after adjusting for age and sun-
sensitivity sun-exposure was negatively associated with AMD. The authors concluded that
sun-sensitivity confounds study of the postulated AMD-sunlight link [73]. The evidence is thus
still lacking to support a definite link between AMD and sun-exposure.
3.5.3. Micronutrients
A significant role for vitamin C in the retina has been indicated by laboratory experiments in
animals. Tso et al showed that under conditions of continuous light exposure, the levels of
ascorbic acid in the retina fell [190]. The same group also demonstrated that ascorbic acid may
protect the retina from light damage [191]. Retinal degeneration can be induced specifically
by anti-oxidant (E and A) vitamin deficiency in monkeys [192]. Zinc is found in high concen‐
trations in the RPE and pathological lesions have been observed in animals deprived of zinc
[193]. Vitamin E and selenium play key roles in preventing in vitro lipid peroxidation and free
radical damage to retinal tissues. Rats fed on diets deficient in vitamin E and/or selenium and
subsequently exposed to hyperbaric oxygen show diminished ERG amplitudes and evidence
of photoreceptor cell necrosis [194]. Carotenoids are vegetable products which are essential to
the health of the eye and are concentrated at the macula- in particular zeaxanthin (found mainly
in maize) and lutein (found mainly in spinach); they may also act as anti-oxidants to scavenge
free radicals.
In light of these experimental findings the EDCCS examined the relationship of micronutrients
to neovascular age-related macular degeneration [64;195]. Serum levels of carotenoids (Lutein/
Zeaxanthin, beta-carotene, alpha-carotene, cryptoxanthin, lycopene), vitamins C and E,
selenium (glutathione peroxidase is selenium dependent and theoretically may reduce the
amount of macular damage from oxidative insult) and zinc in 421 patients with neovascular
age-related macular degeneration and 615 controls were compared. Although no statistically
significant protective effect was found for vitamin C or E or selenium individually, an
antioxidant index that combined all four micronutrient measurements showed statistically
significant reductions of risk with increasing levels of the index. No support was found for
serum zinc levels as a risk factor for neovascular AMD. In a further report dietary intake was
examined in this same study group using food frequency questionnaires. A higher dietary
intake of carotenoids was associated with a 43% lower risk for AMD. Lutein and zeaxanthin
were most strongly associated [196].
Other population studies have not been able to demonstrate a protective effect of the antioxi‐
dant micronutrients. In the Beaver Dam Eye Study a protective effect of higher zinc intake in
early but not late ARM was demonstrated but there was no association with intake of other
antioxidant micronutrients [197]. The study’s main failing may have been with the use of diet
recall from 10 years prior; hence recall bias is likely to be a major factor limiting the ability to
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detect an association. Similarly the third national health and nutrition examination survey
study did not find a link with serum levels of lutein/ zeaxanthin or dietary intake and AMD
in the sample as a whole but only in those with young onset AMD [198]. Again recall bias is
likely to be a major factor influencing the likelihood of detecting an association.
Results from a large clinical trial have indicated that high-dose vitamin supplementation may
reduce vision loss from AMD [199]. The Age-related Eye Disease Study Research Group
developed a double-masked clinical trial in patients with AMD. Treatment with zinc with or
without antioxidant vitamins reduced the risk of progression to advanced AMD in the groups
with more severe AMD at the outset (more specifically these groups were those with extensive
intermediate-sized drusen, large drusen or non-central GA in one or both eyes, or advanced
AMD in one eye). Relative risk estimates suggest a reduced risk of 21% if zinc is taken alone
and 17% for antioxidants the reduced risk if both are taken is 25%. In the less severe AMD
groups at outset the incidence of progression to advanced AMD at 5 years was too low to
establish any effect of supplementation and there was no effect of supplementation on delaying
progression from the less severe groups to more severe groups during the study.
At the time of writing, a multi-center, randomized trial of supplementation with Lutein,
Zeaxanthin, and Omega-3 Long-Chain Polyunsaturated Fatty Acids (the AREDS 2 study) is
underway, with results expected in 2013 [200].
3.5.4. Dietary fat
The major drusen component is neutral lipid and this is also deposited in Bruch’s membrane.
Theories therefore propose AMD as having a similar pathway to atherosclerosis. However,
since the lipid is esterified, it implies the fat arises secondary to being transported out of RPE
cells and does not arise from plasma cholesterol. By contrast, the lipoprotein constituent of
drusen is plasma derived. There are epidemiological studies to support this theory. In one
study dietary linoleic acid (the major fatty-acid component of drusen [151]) was associated
with increased risk of AMD [201]. Generally the epidemiological studies show conflicting
results for dietary fat which may be in part due to the difficulty inherent in food-frequency
questionnaires and associated recall bias or may be further evidence that there is no association
as might be expected from the underlying biology. There appears to be limited evidence for
an association between saturated fatty acid intake and AMD [202]. Seddon et al suggest an
increased risk of AMD prevalence and progression with higher vegetable fat intake [203;204],
and it is hypothesised that this may be due to high levels of trans-fatty acids in some margar‐
ines. Whilst in the BMES there was a reduction of incident AMD with increasing intake of
polyunsaturated fats after 5 years follow-up [205]. Omega-3 fatty acids may protect against
AMD [206;207] and the AREDS2 study is currently underway to further investigate this [200].
3.5.5. Alcohol
There is experimental evidence to suggest alcohol may increase the risk of AMD. A study of
alcohol-fed rats showed that heavy alcohol intake was associated with both an increased
accumulation of ethyl esters in the choroid and an exacerbation of the CNV induced by laser
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treatment [208]. A number of clinical studies have investigated the role of alcohol consumption
and risk of AMD and among these there are studies demonstrating no association [209-211],
weak positive associations for some forms of ARM/ AMD [212-217], or even an inverse
association [146;218]. In a recent systematic review of the literature pooled results showed that
heavy alcohol consumption was associated with an increased risk of early AMD (pooled odds
ratio, 1.47; 95% confidence interval, 1.10 to 1.95), whereas the association between heavy
alcohol consumption and risk of late AMD was inconclusive. There were insufficient data to
evaluate a dose-response association between alcohol consumption and AMD or the associa‐
tion between moderate alcohol consumption and AMD. The authors conclude that although
this association seems to be independent of smoking, residual confounding effects from
smoking cannot be excluded completely [219].
4. Summary
AMD creates a huge burden on society, being the third largest cause of blindness world-wide.
The impact is far reaching in terms of quality of life to the individual as well as financial and
social burdens on society as a whole. AMD appears to have greater representation in white,
Caucasian populations but it is becoming apparent that the prevalence in other ethnic
populations is substantial. There are differences in the sub-type presentation of disease in
different populations.
It appears that AMD is caused by environmental factors triggering disease in genetically
susceptible individuals. Identifying modifiable risk factors is a vital part of defining the
pathogenesis of AMD and enabling appropriate targeting of treatment strategies. Whilst age
is the strongest risk factor for AMD, a number of environmental risk factors have been
proposed and the adverse effect of smoking is well-established.
The data demonstrate a clear association between the risk of AMD and pack-years of cigarette
smoking with odds ratios in some studies demonstrating a dose-related effect. Both types of
AMD show a similar relationship in most studies. Stopping smoking is associated with
reduced odds of AMD. This provides strong support for a causal relationship between
smoking and age-related macular degeneration. Axial length and refractive error also appear
to play a role with most studies indicating increased prevalence associated with hyperopia.
Other possible risk factors include blue iris colour, poor skin tanning or abnormal skin
sensitivity to sunlight but generally the studies show null or only weak association. Hyper‐
tension and other cardiovascular risk factors do seem to play a role but the associations appear
weaker than for smoking and genetic factors. Dietary factors associations are notoriously
difficult to establish but in general there appears to be reduced risk in those with diets higher
in antioxidants and fish but there is only weak evidence for an association with increased
dietary fat intake. Dietary antioxidant supplements such as carotenoids and zinc may be
protective for progression in the later stages of AMD and other dietary supplements are
currently being investigated.
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Genes associated with hereditary retinal dystrophies have been isolated but few appear to
show association with AMD. However, non-retina specific genes appear to be significantly
associated with risk, in particular those involved in complement activation, extracellular
matrix composition, angiogenesis and lipid transport which provides vital evidence for
developing targeted therapy.
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